Autoimmune Disease Treatment Market size was valued at USD 6.63 billion in 2023 and is likely to cross USD 16.98 billion by 2036, registering more than 7.5% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of autoimmune disease treatment is estimated at USD 7.03 billion.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
7.5% |
|
Base Year Market Size (2023) |
USD 6.63 billion |
|
Forecast Year Market Size (2036) |
USD 16.98 billion |
|
Regional Scope |
|
The market is segmented by drug, by disease, by distribution channel and by region. Based on disease, the market is segmented into rheumatoid arthritis, type 1 diabetes, multiple sclerosis, psoriasis, lupus, inflammatory bowel disease and others. The high prevalence of rheumatoid arthritis globally can be attributed to the significantly high share of this segment in the market over the next few years. On the basis of drugs, the market is segmented into NSAIDs, anti-inflammatory, interferons, antihyperglycemics and others, out of which, the anti-inflammatory segment is anticipated to hold the largest share in the autoimmune disease treatment market on account of their application in large number of indications such as rheumatoid arthritis, juvenile idiopathic arthritis, gout, psoriasis, ankylosing spondylitis and others. XELJANZ, a drug for oral use manufactured by Pfizer and approved by the U.S. FDA in 2012, aimed at treating both rheumatoid arthritis and psoriatic arthritis among adult patients having an inadequate response to methotrexate.
Our in-depth analysis of the global market includes the following segments
|
By Drug |
|
|
By Disease |
|
|
By Distribution Channel |
|
On the basis of regional analysis, the autoimmune disease treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. North America industry is poised to account for largest revenue share by 2036, as a result of rising research and development activities focused on finding a treatment for autoimmune disease. Moreover, the increasing investment in the healthcare sector in the region is another factor estimated to result in the market growth in the coming years. The highest growth rate of autoimmune disease treatment market is anticipated to be observed in the Asia Pacific region on account of significantly improving healthcare infrastructure and development of better treatment facilities. The growing awareness among people about autoimmune disease further raises the demand for the drugs in the region which is another growth driving factor for the autoimmune disease treatment market over the forecast period.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?